BACKGROUND: Posaconazole is a triazole with anti-Aspergillus activity. However, little is known about the utility of posaconazole as primary therapy for invasive pulmonary aspergillosis. METHODS: An in vitro model of the human alveolus was used to study the impact of minimum inhibitory concentrations (MIC) on exposure-response relationships. The pharmacokinetic-pharmacodynamic relationships of posaconazole were examined in an inhalational murine model of invasive pulmonary aspergillosis. A mathematical model was fitted to the entire data set. This model was then used to describe the relationship between drug exposure, quantified in terms of the area under the concentration time curve to MIC (AUC:MIC) and the observed antifungal effect. RESULTS: The posaconazole MIC was an important determinant of exposure-response relationships and accounted for a portion of the observed variance. Murine pharmacokinetics were linear for dosages 1-20 mg/kg/day. There was a dose-dependent decline in serum galactomannan concentrations, with near-maximal suppression following 20 mg/kg/day. The murine pharmacokinetic-pharmacodynamic data were well described by the mathematical model. An AUC:MIC ratio of 167 was associated with half-maximal antifungal effect. CONCLUSIONS: These results provide the experimental foundation for the selection of candidate posaconazole regimens for the primary treatment of invasive pulmonary aspergillosis in profoundly neutropenic hosts.
BACKGROUND:Posaconazole is a triazole with anti-Aspergillus activity. However, little is known about the utility of posaconazole as primary therapy for invasive pulmonary aspergillosis. METHODS: An in vitro model of the human alveolus was used to study the impact of minimum inhibitory concentrations (MIC) on exposure-response relationships. The pharmacokinetic-pharmacodynamic relationships of posaconazole were examined in an inhalational murine model of invasive pulmonary aspergillosis. A mathematical model was fitted to the entire data set. This model was then used to describe the relationship between drug exposure, quantified in terms of the area under the concentration time curve to MIC (AUC:MIC) and the observed antifungal effect. RESULTS: The posaconazole MIC was an important determinant of exposure-response relationships and accounted for a portion of the observed variance. Murine pharmacokinetics were linear for dosages 1-20 mg/kg/day. There was a dose-dependent decline in serum galactomannan concentrations, with near-maximal suppression following 20 mg/kg/day. The murine pharmacokinetic-pharmacodynamic data were well described by the mathematical model. An AUC:MIC ratio of 167 was associated with half-maximal antifungal effect. CONCLUSIONS: These results provide the experimental foundation for the selection of candidate posaconazole regimens for the primary treatment of invasive pulmonary aspergillosis in profoundly neutropenic hosts.
Authors: William W Hope; Michael J Kruhlak; Caron A Lyman; Ruta Petraitiene; Vidmantas Petraitis; Andrea Francesconi; Miki Kasai; Diana Mickiene; Tin Sein; Joanne Peter; Amy M Kelaher; Johanna E Hughes; Margaret P Cotton; Catherine J Cotten; John Bacher; Sanjay Tripathi; Louis Bermudez; Timothy K Maugel; Patricia M Zerfas; John R Wingard; George L Drusano; Thomas J Walsh Journal: J Infect Dis Date: 2006-12-21 Impact factor: 5.226
Authors: A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad Journal: Antimicrob Agents Chemother Date: 2006-02 Impact factor: 5.191
Authors: Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez Journal: N Engl J Med Date: 2007-01-25 Impact factor: 91.245
Authors: Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant Journal: N Engl J Med Date: 2007-01-25 Impact factor: 91.245
Authors: M Cuenca-Estrella; M C Arendrup; E Chryssanthou; E Dannaoui; C Lass-Florl; P Sandven; A Velegraki; J L Rodriguez-Tudela Journal: Clin Microbiol Infect Date: 2007-08-13 Impact factor: 8.067
Authors: Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect Journal: Clin Infect Dis Date: 2006-11-28 Impact factor: 9.079
Authors: R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh Journal: Antimicrob Agents Chemother Date: 2001-03 Impact factor: 5.191
Authors: Harrys A Torres; Ray Y Hachem; Roy F Chemaly; Dimitrios P Kontoyiannis; Issam I Raad Journal: Lancet Infect Dis Date: 2005-12 Impact factor: 25.071
Authors: P Campoli; Q Al Abdallah; R Robitaille; N V Solis; J A Fielhaber; A S Kristof; M Laverdiere; S G Filler; D C Sheppard Journal: Antimicrob Agents Chemother Date: 2011-09-19 Impact factor: 5.191
Authors: Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin Journal: Cold Spring Harb Perspect Med Date: 2014-11-10 Impact factor: 6.915
Authors: Silke Gastine; William Hope; Georg Hempel; Ruta Petraitiene; Vidmantas Petraitis; Diana Mickiene; John Bacher; Thomas J Walsh; Andreas H Groll Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191
Authors: Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton Journal: Antimicrob Agents Chemother Date: 2014-02-24 Impact factor: 5.191
Authors: Seyedmojtaba Seyedmousavi; Willem J G Melchers; Johan W Mouton; Paul E Verweij Journal: Antimicrob Agents Chemother Date: 2013-02-04 Impact factor: 5.191